Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

Look­ing to ex­pand its on­col­o­gy pipeline, As­traZeneca has turned to the east to pick up a next-gen drug against an emerg­ing tar­get.

Har­bour Bio­Med, a Shang­hai-based out­fit that al­so has siz­able teams in Cam­bridge, MA and Rot­ter­dam, Nether­lands, is out-li­cens­ing its CLDN18.2xCD3 bis­pe­cif­ic an­ti­body to As­traZeneca in ex­change for $25 mil­lion up­front and up to $325 mil­lion in mile­stones plus roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER